A Novel Heterologous Prime Boost Vaccine System To Drive Tumor Specific T Cell Responses For Cancer Immunotherapy

Time: 10:00 am
day: Day One


  • Development of a potent heterologous prime/boost immunization approach
    to deliver predicted TSNAs to patients, which is comprised of a replication
    incompetent chimpanzee adenoviral vector (ChAdV) for the prime vaccination
    and a self-replicating, synthetic viral vector (srRNA) for repeated boost
  • Induction of high titer, polyfunctional and durable T-cell responses against nonself
  • Clinical trial updates will be highlighted